Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia

Chemotherapy

Volumn 45, Issue 3, 1999, Pages 205-212

  Martino, Rodrigo ^a   Subirá, Maricel ^a   Domingo Albós, Andreu ^a   Sureda, Anna ^a   Brunet, Salut ^a   Sierra, Jordi ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Amphotericin B lipid complex; Hematologic malignancy; Neutropenic fever

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; LIVER ENZYME; UREA;

ADULT; AGED; ARTICLE; BLOOD DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; UREA BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG COMBINATIONS; FEMALE; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; TREATMENT OUTCOME;

EID: 0032945447     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007184     Document Type: Article

References (21)

1. Walsh TJ, Hiemenz JW, Anaissie E: Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin N Am 1996;10:365-401.
2. Martino R, Sureda A, Pericas R, Domingo-Albós A, Brunet S: Clinical presentation and diagnosis of invasive fungal infections in immunocompromised hosts. Haematologica 1997;82(suppl 1):179-187.
3. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12: 308-329.
4. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996;22(suppl 2): S133-S144.
5. Leenders ACAP, de Marie S: The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996;10:1570-1575.
6. Walsh TJ, Hiemenz JW, Seibel N, Perfect J, Horwith G, Lee L, Silber J, DiNubile M, Reboli A, Lister J, Bow E, Anaissie EJ: Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases (abstract P-568); in: Abstracts 13th Congr Int Soc Human and Animal Mycology, Parma, Italy, 1997, p 568.
7. Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE: Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Clin Microbiol Infect Dis 1997;16:424-436.
8. Martino R, López R, Sureda A, Brunet S, Domingo-Albós A: Risk of reactivation of a recent invasive fungal infection in patients with hematologic malignancies undergoing further intensive chemo-radiotherapy: A single-center experience and review of the literature. Haematologica 1997;82:297-304.
9. Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P, Weinberger M, Roilides E, Marshall D, Gress J: Empirical amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496-511.
10. Pizzo PA, Robichaud RJ, Gill FAS, Witebsky FG: Empiric therapy with amphotericin B in febrile granulocytopenic patients. Am J Med 1982; 72:101-111.
11. EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:608-612.
12. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
13. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718.
14. Walsh T, Bodensteiner D, Hiemenz J, Thaler S, Greenberg R, Arndt C, Holcenberg J, Schwartz C, Pappas P, Dummer S, Marsh R, Schuster M, Seibel N: A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus Amphotericin B in the empirical treatment of persistently febrile neutropenic patients (abstract LM-90); in: Program and abstracts 37th Intersci Conf Antimicrobial Agents and Chemotherapy (Toronto). Washington, American Society for Microbiology, 1997, p 76.
15. Lister J: Amphotericin B lipid complex (Abelcet®) in the treatment of invasive mysoses: The North American experience. Eur J Haematol 1996;56(suppl 57):18-23.
16. Rapp RP, Gubbins PO, Evans ME: Amphotericin B lipid complex. Ann Pharmacother 1997;31:1174-1186.
17. Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RA: Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997;41:2201-2208.
18. Linden P: Efficacy of low-dose Abelcet (amphotericin B lipid complex) (abstract 268); in: Abstracts of Focus on Fungal Infections 7, San Antonio, 1997, p 28.
19. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC Jr, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-321.
20. Rogers J, Conway A: Tolerability of low dose amphotericin B lipid complex (Abelcet®) for the treatment of pyrexia of unknown origin (PUO) in neutropenic cancer patients (abstract 493). Bone Marrow Transplant 1998;21(suppl 1):S143.
21. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW: Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127: 133-137.